Filing Details
Akari Therapeutics Plc (NASDAQ:AKTX) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event.
8k filedNASDAQ:AKTX
Akari Therapeutics Plc (AKTX) Reports Material Event to SEC
Filing Details Akari Therapeutics Plc (NASDAQ:AKTX) filed a Form 8-K with the Securities and Exchange Commission on July 02, 2026, disclosing a material event. Market Context…
Market Context
Akari Therapeutics Plc's stock currently trades at $10.41 with a market capitalization of $4.2K. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Akari Therapeutics Plc's stock.
All SEC filings for Akari Therapeutics Plc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AKTX Stock Page
Frequently Asked Questions
Where can I read AKTX's SEC filings?
Browse all filings on our AKTX SEC filings page.
What types of SEC filings does Akari Therapeutics Plc file?
Public companies like Akari Therapeutics Plc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
